PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
 
Antimicrob Agents Chemother. 2013 March; 57(3): 1559–1560.
PMCID: PMC3591876

Outbreak of Infections Caused by Shigella sonnei with Reduced Susceptibility to Azithromycin in the United States

LETTER

Shigellosis is the third most common enteric bacterial infection in the United States (1). The disease is caused by Shigella bacteria, and symptoms include abdominal cramps, diarrhea that sometimes contains blood, nausea, vomiting, and fever. Shigella sonnei has a very low infectious dose, and the infection may spread from person to person or via contaminated objects, food, or water. In the United States, the incidence is highest among children who are <5 years old, and multiple outbreaks of S. sonnei infections have been associated with daycare centers (2, 3).

In the United States, shigellosis is frequently treated with antimicrobial drugs because they can slightly shorten the duration and severity of illness (4). Increasing resistance to ampicillin and trimethoprim-sulfamethoxazole has led physicians to prescribe azithromycin for treatment of shigellosis (3, 5). Azithromycin is currently recommended by the American Academy of Pediatrics and the Infectious Diseases Society of America for the treatment of multidrug-resistant shigellosis, although azithromycin susceptibility testing guidelines and interpretive criteria are lacking for Shigella (6, 7). A study by Howie et al. showed the susceptible wild-type distribution of MICs to range from 4 to 16 μg/ml (8). Isolates with higher azithromycin MICs have been confirmed to harbor mphA, a macrolide resistance gene encoding a macrolide-2′-phosphotransferase (8, 9).

In May 2012, the Los Angeles County Department of Public Health (Los Angeles County, CA) investigated an outbreak caused by S. sonnei that sickened 43 people. Four representative isolates (2012C-3667 to 2012C-3670) were submitted to the Centers for Disease Control and Prevention (CDC). Two isolates were obtained from asymptomatic, male employees of a bridge club, one of whom was a food handler. Two isolates were obtained from women in the same club. Both women were hospitalized with nonbloody diarrhea; one was ill for 7 days and reported vomiting and fever of 102°F; the duration of illness was not reported for the other. The ages of these four individuals ranged from 60 to 89 years.

The isolates yielded indistinguishable patterns by pulsed-field gel electrophoresis (PFGE) using XbaI (PulseNet pattern J16X01.0756). Susceptibility to 14 antimicrobial agents was determined by broth microdilution (Sensititre; Trek Diagnostics, Westlake, OH). All four isolates displayed resistance to streptomycin, sulfisoxazole, tetracycline, and trimethoprim-sulfamethoxazole. In addition, all four isolates displayed azithromycin MICs of >16 μg/ml (Table 1). PCR screening confirmed the presence of mphA in all four isolates (8). Plasmid DNA from two isolates was electroporated into Escherichia coli DH10B cells. E. coli transformants with elevated MICs to azithromycin (MIC > 16 μg/ml) confirmed the mphA gene to be located on a plasmid. The plasmid type could not be determined by inc/rep typing (10).

Table 1
MICs for Shigella sonnei and Escherichia coli isolatesa

To our knowledge, this is the first outbreak caused by Shigella isolates displaying elevated azithromycin MICs to be documented within the United States. The circulation of Shigella isolates with high azithromycin MICs is worrisome, since it may limit the treatment options for multidrug-resistant infections, especially among children.

Footnotes

Published ahead of print 28 December 2012

REFERENCES

1. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, Jones JL, Griffin PM. 2011. Foodborne illness acquired in the United States–major pathogens. Emerg. Infect. Dis. 17:7–15. [PMC free article] [PubMed]
2. Arvelo W, Hinkle CJ, Nguyen TA, Weiser T, Steinmuller N, Khan F, Gladbach S, Parsons M, Jennings D, Zhu BP, Mintz E, Bowen A. 2009. Transmission risk factors and treatment of pediatric shigellosis during a large daycare center-associated outbreak of multidrug resistant Shigella sonnei: implications for the management of shigellosis outbreaks among children. Pediatr. Infect. Dis. J. 28:976–980. [PubMed]
3. Shiferaw B, Solghan S, Palmer A, Joyce K, Barzilay EJ, Krueger A, Cieslak P. 2012. Antimicrobial susceptibility patterns of Shigella isolates in Foodborne Diseases Active Surveillance Network (FoodNet) sites, 2000–2010. Clin. Infect. Dis. 54(Suppl. 5):S458–S463. [PubMed]
4. Christopher PRH, David KV, John SM, Sankarapandian V. 2010. Antibiotic therapy for Shigella dysentery. Cochrane Database Syst. Rev. 2010(8):CD006784 doi:10.1002/14651858.CD006784.pub4. [PubMed]
5. Basualdo W, Arbo A. 2003. Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. Pediatr. Infect. Dis. J. 22:374–377. [PubMed]
6. American Academy of Pediatrics 2012. Shigella infections, p 645–647 In Pickering LK, Baker CJ, Kimberlin DW, Long SS, editors. (ed), Red book: 2012 report of the Committee on Infectious Diseases, 29th ed American Academy of Pediatrics, Elk Grove Village, IL.
7. Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV, Hennessy T, Griffin PM, DuPont H, Sack RB, Tarr P, Neill M, Nachamkin I, Reller LB, Osterholm MT, Bennish ML, Pickering LK. 2001. Practice guidelines for the management of infectious diarrhea. Clin. Infect. Dis. 32:331–351. [PubMed]
8. Howie RL, Folster JP, Bowen A, Barzilay EJ, Whichard JM. 2010. Reduced azithromycin susceptibility in Shigella sonnei, United States. Microb. Drug Resist. 16:245–248. [PubMed]
9. Boumghar-Bourtchai L, Mariani-Kurkdjian P, Bingen E, Filliol I, Dhalluin A, Ifrane SA, Weill FX, Leclercq R. 2008. Macrolide-resistant Shigella sonnei. Emerg. Infect. Dis. 14:1297–1299. [PMC free article] [PubMed]
10. Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. 2005. Identification of plasmids by PCR-based replicon typing. J. Microbiol. Methods 63:219–228. [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)